We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Therapy Prevents Skin Cancer

By Biotechdaily staff writers
Posted on 29 Dec 2004
Researchers have used gene therapy to eliminate the tendency to develop skin cancer after exposure to ultraviolet (UV) light in a mouse model for the rare inherited disease called xeroderma pigmentosum (XP).

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA; www.utsouthwestern.edu) created a line of mice that mimicked the human form of XP by having a mutated form of the gene XPA in their skin cells. More...
These cells were unable to repair damage to DNA caused by exposure to UV light. The damaged DNA caused abnormal cell growth and development leading to tumor formation and early death of the animals.

In the present study, which was published in the December 14, 2004, online edition of the Proceedings of the [U.S.] National Academy of Sciences, the investigators used a genetically engineered adenovirus vector to inject the normal human XPA gene into the skin cells of the XP mice. The animals were then exposed to UV light for a few hours over a period of several days. The treated mice did not develop skin lesions or tumors and were as healthy as normal controls five months after UV exposure.

"Gene therapy for XP has the potential to completely prevent cancer in a group of patients who otherwise may suffer no other ill effects from their genetic defect,” said senior author Dr. Errol Friedberg, professor of pathology at the University of Texas Southwestern Medical Center. "XP is a disease that lends itself well to gene therapy, for a variety of reasons. Most importantly, skin cells are highly accessible for introducing foreign genes. Also, infection of the skin with a virus carrying the gene of interest, as we did with the mice, allows for many, many cells to receive the appropriate gene. Once some of the existing technical limitations are solved, these studies can hopefully be extended to trials with human XP patients.”

New
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Steam Sterilizer
Hi Vac II Line
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.